Global Cannabis Applications Corp. (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF), a leading developer of innovative data technologies for the cannabis industry, is pleased to announce that it will participate in a medical cannabis study on the effects of cannabis on mental health conducted by Dr. Alasdair Barr.

GCAC will support Dr. Alasdair Barr, PhD, in a medical cannabis research study conducted by the University of British Columbia on the effects of cannabis on mental health. The study will be applied using semi-structured clinical interviews with instruments commonly applied to clinical trials in order to investigate a population of people in Vancouver, BC who suffer from mental health issues and choose to self-medicate with medical cannabis. By using clinical interviews and questionnaires, the results of the study are expected to gain a more thorough understanding of the population that uses medical cannabis, including the frequency and specific type of cannabis cultivars used for specific symptoms or disorders. Medical cannabis can be used for a wide variety of different medical conditions, but the large majority of patients use it for its psychological effects, such as for anxiety, depression, pain and insomnia.

Dr. Alasdair Barr is an Associate Professor at the University of British Columbia with a focus on mental health and addictions research, using a multidisciplinary and translational approach that spans from laboratory to clinic. Dr. Barr maintains active programs in both clinical and preclinical research and has been published in over 150 peer-reviewed articles. Dr. Barr is active in the cannabis space and serves as a scientific consultant to multiple cannabis based companies.

“I am happy that Global Cannabis is joining our efforts to provide further information about potentially better treatments for mental health” said Dr. Barr. “Mental illness will affect more than half of all Canadians during their lifetime. Traditionally, mental illness is treated with pharmacological drugs that can come with unwanted side effects. Many patients have therefore started looking for alternatives to “big pharma” medications, and in this search have found medical cannabis to be helpful. Though there is limited research supporting many of its benefits, the role of cannabis in mental health is still unclear and therefore requires further investigation, as many epidemiological studies obtain only superficial data about current mental health status.”

States GCAC CEO Brad Moore, “We are honoured to work with Dr. Barr in his invaluable work on studying the effects of medical cannabis on mental health. The results of this invaluable information will help provide clarity on the benefits of medical cannabis and will enhance the data on the Citizen Green technology platform and GCAC’s ‘Pain to Strain’ model.”

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing, and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, reg tech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in medical cannabis. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more information about the Company, please visit online at, or review its profiles and on the Canadian Securities Exchange’s website (

To schedule an interview, please contact:

Bradley Moore

Chief Executive Officer

Telephone: 514-5619091


For more information, please contact:

Corporate Communications

Telephone: 1.855.269.9554


Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

Click here to connect with Global Cannabis Applications Corp. and receive an Investor’s Presentation.


Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email or for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less